Resource Center - Persevere Therapeutics : Persevere Therapeutics

publication

Publication Summary – Misetionamide (GP-2250)

A summary of all publications with links to full document

poster

Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors

publication

Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian cancer.

Mark Kim, Deanna Glassman, Katelyn F Handley, Adrian Lankenau ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Robert L. Coleman and Anil K. Sood.

publication

Antineoplastic activity of GP-2250 in-vitro and in mouse xenograft models

R. Duane Soﬁa, Kathryn M. Martin and James C. Costin

publication

Increasing the cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin on pancreatic cancer cells through combination with the novel anticancer agent GP-2250 in vitro

I.Peters; B. Majchrzak-Stiller ; M. Buchholz ; P. Höhn ; W. Uhl ; C. Braumann ; J. Strotmann

publication

GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells

Britta Majchrzak- Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler

publication

Oxathiazinane Derivatives Display Both Anticancer and Antibacterial Activity: A Structure Activity Study

B. Majchrzak Stiller, M. Buchholz, I. Peters, J. Strotmann, J. Möhrke, L. Zelichowski, L. Oehlke, C. Quensel, D. Fein, P. Höhn, T. Müller, W. Uhl, C. Braumann May 12, 2023

publication

An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results

Milan Barras, Lutz Schmitz, Chris Braumann, Waldemar Uhl, Marina Skrygan, Marie Buchholz, Thomas Meyer, Eggert Stockfleth, Thomas Müller, Jürgen C. Becker and Thilo Gambichler

publication

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

Thilo Gambichler, Britta Majchrzak-Stiller, Ilka Peters, Jürgen C Becker, Johanna Strotmann, Nessr Abu Rached, Thomas Müller, Waldemar Uhl 2, Marie Buchholz, Chris Braumann

publication

Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer

American Association for Cancer Research (AACR) Annual Meeting 2023

Mark S. Kim, Deanna Glassman, Adrian Lankenau Ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Sanghoon Lee, Robert L. Coleman, Anil K. Sood

publication

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

Thilo Gambichler , Friederike Harnischfeger , Marina Skrygan , Britta Majchrzak-Stiller , Marie Buchholz , Thomas Müller and Chris Braumann

publication

Substance GP-2250 as a new therapeutic agent for malignant peritoneal mesothelioma – a 3-D in vitro study

Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann and Chris Braumann

publication

A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.

A. Kasi, J. L. Iglesias.

publication

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller, Stephan Hahn 2, Ilka Peters, Julian Horn Thomas Müller, Philipp Höhn, Waldemar Uhl and Chris Braumann

publication

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. Journal of Clinical Oncology Vol. 28, No. 15-suppl. May 2020

C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.)

publication

Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik.

publication

Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, R.W. Pfirrmann, A.M. Chromik, W. Uhl.